Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Valneva
Biotech
Pfizer, Valneva miss Lyme shot ph. 3 goal but plan approval push
Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its key goal.
James Waldron
Mar 23, 2026 6:45am
Valneva closes site to consolidate R&D footprint, lays off 30
Nov 26, 2025 12:57pm
Pfizer, Valneva boosted by updated Lyme vaccine data
Sep 3, 2025 10:19am
Pfizer, Valneva show Lyme disease shot effective for 2nd booster
Sep 3, 2024 4:30am
Valneva pays LimmaTech $10M for clinical-stage Shigella vaccine
Aug 1, 2024 8:26am
Valneva sells priority review voucher for $103M, R&D to benefit
Feb 5, 2024 9:15am
